SELLAS Life Sciences Group Inc sell daimler1
Start price
07:59
/
50%
€2.50
Target price
29.12.26
-
Performance (%)
14.40%
Price
21:22
€2.86
Summary
This prediction is currently active. The prediction currently has a disappointing performance of 14.40%. This prediction currently runs until 29.12.26. The prediction end date can be changed by daimler1 at any time. daimler1 has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | 14.40% |
| iShares Core DAX® | 0.224% |
| iShares Nasdaq 100 | 0.371% |
| iShares Nikkei 225® | 0.972% |
| iShares S&P 500 | 0.417% |
Comments by daimler1 for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Sell SELLAS Life Sciences Group Inc